Toshinori Sueda
Papers
4
Total Citations
33
H-Index
3
About
Toshinori Sueda is a leading surgical oncologist whose research focuses on advanced gastric and gastroesophageal junction cancers, particularly the integration of targeted therapies and minimally invasive surgical techniques. His work has been instrumental in evaluating the real-world efficacy and safety of zolbetuximab, a monoclonal antibody targeting CLDN18.2-positive tumors, as demonstrated in his 2025 study on protein-losing enteropathy—a critical adverse event emerging from the landmark GLOW and SPOTLIGHT trials. Sueda has also made significant contributions to comparative surgical outcomes, with his 2021 propensity score-matched analysis of robotic versus laparoscopic surgery for rectal cancer (8 citations) and his 2025 investigation of robotic and laparoscopic gastrectomy (10 citations) providing key insights into perioperative performance and three-year survival. His exploration of conversion surgery following zolbetuximab-based chemotherapy (2 citations) further highlights his commitment to expanding treatment options for patients with unresectable disease. With over 33 citations across his most influential papers, Sueda’s research bridges the gap between novel pharmacotherapies and surgical innovation, offering practical guidance for clinicians managing complex gastrointestinal malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4